Eli Lilly's late-stage pipeline features such products as retatrutide, a potential novel weight loss treatment. Eli Lilly broke new ground with Zepbound. It's a dual GLP-1/GIP agonist, meaning it ...

This is on top of NVO's promising pipeline, amycretin, offering accelerated weight loss results compared to CagriSema and LLY's Zepbound/ Retatrutide. Even so, we had believed that FY2025 was ...

For Kristian Cook, every pizza box he opened was another door closed on the path to overcoming obesity. “I had massive cravings for pizza,” he says. “That was my biggest downfall.” ...

Chinese companies are enticing investors with record dividend payouts, with some market watchers saying more are on the horizon. "Companies don't know where to put their cash... so they return it ...

Chinese companies are enticing investors with record dividend payouts, with some market watchers saying more are on the horizon. "Companies don't know where to put their cash... so they return it ...

It also reported preliminary data with an oral triple agonist called retatrutide – targeting GLP-1, GIP, and glucagon – that is also being advanced quickly into phase 3. Shares in Pfizer fell ...